ATLAS: A phase 3 trial evaluating the efficacy of apalutamide (ARN-509) in patients with high-risk localized or locally advanced prostate cancer receiving primary radiation therapy

被引：2
|
作者：
Bossi, A. [1 ]
Dearnaley, D. [2 ,3 ]
McKenzie, M. [4 ]
Baskin-Bey, E. [5 ]
Tyler, R. [5 ]
Tombal, B. [6 ]
Freedland, S. J. [7 ]
Roach, M., III [8 ]
Widmark, A. [9 ]
Dicker, A. P. [10 ]
Wiegel, T. [11 ]
Shore, N. [12 ]
Smith, M. [13 ,14 ]
Yu, M. [5 ]
Kheoh, T. [15 ]
Thomas, S. [16 ]
Sandler, H. M. [17 ]
机构：
[1] Inst Gustave Roussy, Radiat Oncol, Villejuif, France
[2] Inst Canc Res, Acad Radiotherapy, London, England
[3] Royal Marsden Hosp, London, England
[4] British Columbia Canc Agcy, Med Oncol, Vancouver, BC, Canada
[5] Janssen Res & Dev, WC Clin Oncol, Los Angeles, CA USA
[6] Clin Univ St Luc, Urol, Brussels, Belgium
[7] Cedars Sinai Med Ctr, Surg, Los Angeles, CA 90048 USA
[8] Univ Calif San Francisco, Radiat Oncol, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA
[9] Umea Univ, Radiat Sci, Umea, Sweden
[10] Thomas Jefferson Univ, Radiat Oncol, Philadelphia, PA 19107 USA
[11] Ulm Med Univ, Radiat Oncol, Ulm, Germany
[12] Carolina Urol Res Ctr, Urol, Myrtle Beach, SC USA
[13] Massachusetts Gen Hosp, Ctr Canc, Hematol Oncol, Boston, MA USA
[14] Harvard Med Sch, Boston, MA USA
[15] Janssen Res & Dev, Clin Biostat, San Diego, CA USA
[16] Janssen Pharmaceut, Oncol Translat Res, Spring House, PA USA
[17] Cedars Sinai Med Ctr, Radiat Oncol, Los Angeles, CA 90048 USA
来源：
ANNALS OF ONCOLOGY | 2016年 / 27卷
关键词：
D O I：
10.1093/annonc/mdw372.52
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
769TiP
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Post-Metastasis Survival of Patients with High-Risk Localized and Locally Advanced Prostate Cancer Undergoing Primary Treatment in the United States: A Retrospective Study
    Freedland, Stephen J.
    Fernandes, Luis
    De Solda, Francesco
    Buyukkaramikli, Nasuh
    Mundle, Suneel D.
    McCarthy, Sharon A.
    Labson, Daniel
    Yang, Lingfeng
    Pan, Feng
    Mir, Carmen
    TARGETED ONCOLOGY, 2025, 20 (01) : 139 - 148
  • [42] PROTEUS: A randomized, double-blind, placebo (PBO)-controlled, phase 3 trial of apalutamide (APA) plus androgen deprivation therapy (ADT) versus PBO plus ADT prior to radical prostatectomy (RP) in patients with localized high-risk or locally advanced prostate cancer (PC).
    Taplin, Mary-Ellen
    Gleave, Martin
    Evans, Christopher P.
    Efstathiou, Eleni
    Kantoff, Philip W.
    Ross, Ashley
    Shore, Neal D.
    Briganti, Alberto
    Hadaschik, Boris A.
    Heidenreich, Axel
    Rooney, Oliver Brendan
    Tian, Shaozhou Ken
    Wetherhold, Lisa
    Xu, Weichun
    Cheng, Shinta
    Kibel, Adam S.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [43] PATIENT RETENTION AND PHYSICIAN ENGAGEMENT STRATEGIES DURING THE COVID-19 PANDEMIC IN THE PHASE 3 ATLAS STUDY OF APALUTAMIDE ADDED TO ANDROGEN DEPRIVATION THERAPY IN HIGHRISK LOCALIZED OR LOCALLY ADVANCED PROSTATE CANCER
    Sutton, Jennifer
    Shore, Neal D.
    Mundle, Suneel D.
    Brookman-May, Sabine D.
    Feng, Felix
    ONCOLOGY NURSING FORUM, 2023, 50 (02)
  • [44] Early Endpoints in High-risk Localized Prostate Cancer: Exploratory Analysis of Three Radiation Therapy Oncology Group Phase 3 Studies
    Feng, Felix
    Miladinovic, Branko
    Zhang, Ke
    Dignam, James J.
    Wang, Daniel
    Yu, Margaret
    Sandler, Howard
    EUROPEAN UROLOGY, 2023, 84 (03) : 331 - 340
  • [45] Adjuvant Therapy in High-Risk Prostate Cancer after Radical Prostatectomy A Randomized, open-label, Phase 2 Study of Adjuvant Apalutamide or Standard of Care in Subjects with High-risk, Localized or Locally Advanced Prostate Cancer After Radical Prostatectomy (ADAM) - Study AP 116/21 of AUO
    Rexer, Heidrun
    Boegemann, Martin
    Graefen, Markus
    AKTUELLE UROLOGIE, 2023, 54 (01) : 21 - 23
  • [46] A phase II trial of neoadjuvant docetaxel and estramustine followed by radical prostatectomy or radiation therapy for patients with high-risk prostate cancer
    Goyal, L. K.
    Ramsey, S. N.
    Godley, P.
    Pruthi, R.
    Wallen, E.
    Whang, Y.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2006, 66 (03): : S362 - S362
  • [47] Pelvic Nodal Dosing With Registration to the Prostate: Implications for High-Risk Prostate Cancer Patients Receiving Stereotactic Body Radiation Therapy
    Kishan, Amar U.
    Lamb, James M.
    Jani, Shyam S.
    Kang, Jung J.
    Steinberg, Michael L.
    King, Christopher R.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2015, 91 (04): : 832 - 839
  • [48] PRIMARY RADIOTHERAPY AND HORMONE THERAPY IN PATIENTS WITH HIGH-RISK PROSTATE CANCER: PRELIMINARY RESULTS OF A RANDOMIZED TRIAL
    Ibraimova, M.
    Kim, V.
    Kyzy, Z. Syrymbet
    RADIOTHERAPY AND ONCOLOGY, 2011, 99 : S387 - S387
  • [49] PROTEUS: A randomized, double-blind, placebo (PBO)-controlled, phase 3 trial of apalutamide (APA) plus androgen deprivation therapy (ADT) versus PBO plus ADT prior to radical prostatectomy (RP) in patients (pts) with localized or locally advanced high-risk prostate cancer (PC).
    Kibel, Adam S.
    Gleave, Martin
    Brookman-May, Sabine D.
    Kim, Won
    Evans, Christopher P.
    Efstathiou, Eleni
    Kantoff, Philip W.
    Ross, Ashley
    Shore, Neal D.
    Briganti, Alberto
    Hadaschik, Boris A.
    Heidenreich, Axel
    Rooney, Oliver Brendan
    Tian, Shaozhou Ken
    Wetherhold, Lisa
    Xu, Weichun
    Parsons, J. Kellogg
    Yeruva, Kesav
    Taplin, Mary-Ellen
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [50] Influence of Timing Between Androgen Deprivation Therapy and External Beam Radiation Therapy in Patients with Localized, High-Risk Prostate Cancer
    McCall, N. S.
    Liu, Y.
    Patel, S. A.
    Hershatter, B.
    Moghanaki, D.
    Godette, K. D.
    Hanasoge, S.
    Patel, P. R.
    Fischer-Valuck, B. W.
    Shelton, J. W.
    Jani, A.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2020, 108 (03): : E877 - E877
12345